Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

Richard Harris, MD
Published: Friday, Nov 04, 2016


Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his thoughts during an interview with OncLive at the 2016 LUGPA Annual Meeting.

With regard to early diagnosis, genomic markers can help establish how aggressive a biopsy is and give urologists guidance on whether patients should be placed under active surveillance or treated.

Additionally, many new therapies are in clinical development for advanced prostate cancer. In this space, many clinical trials are looking at PARP inhibitors, which have a very bright future as far as helping manage certain forms of prostate cancer, Harris says.

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his thoughts during an interview with OncLive at the 2016 LUGPA Annual Meeting.

With regard to early diagnosis, genomic markers can help establish how aggressive a biopsy is and give urologists guidance on whether patients should be placed under active surveillance or treated.

Additionally, many new therapies are in clinical development for advanced prostate cancer. In this space, many clinical trials are looking at PARP inhibitors, which have a very bright future as far as helping manage certain forms of prostate cancer, Harris says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x